These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38727887)

  • 1. Safety of Combined Statin and Fibrate Therapy: Risks of Liver Injury and Acute Kidney Injury in a Cohort Study from the Shizuoka Kokuho Database.
    Sobukawa Y; Hatta T; Funaki D; Nakatani E
    Drugs Real World Outcomes; 2024 Jun; 11(2):317-330. PubMed ID: 38727887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
    Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
    Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of fibrates is not associated with reduced risks of mortality or cardiovascular events among ESRD patients: A national cohort study.
    Ho WY; Yen CL; Lee CC; Tu YR; Chen CY; Hsiao CC; Chu PH; Hsu HH; Tian YC; Chang CH
    Front Cardiovasc Med; 2022; 9():907539. PubMed ID: 36440016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pleiotropic effects of statins vs fibrates on laboratory parameters in patients with dyslipidemia: A retrospective cohort study.
    Takeuchi S; Takahashi Y; Asai S
    Medicine (Baltimore); 2020 Dec; 99(50):e23427. PubMed ID: 33327270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can Concurrent Fibrate Use Reduce Cardiovascular Risks among Moderate Chronic Kidney Disease Patients Undergoing Statin Therapy? A Cohort Study.
    Ma LY; Fan PC; Chen CY; Tu YR; Hsiao CC; Yen CL; Chang CH
    J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
    Pariente A; Labat V; Mansiaux Y; Salvo F; Bégaud B; Raschi E; Faillie JL; Létinier L; Bezin J
    Drug Saf; 2020 Aug; 43(8):767-774. PubMed ID: 32306223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias.
    Suh HS; Hay JW; Johnson KA; Doctor JN
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):470-84. PubMed ID: 22461130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
    Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
    JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Acta Cardiol; 2003 Jun; 58(3):179-84. PubMed ID: 12846506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG; Lee JY; Kang BC
    Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of COPD Exacerbations Associated with Statins versus Fibrates: A New User, Active Comparison, and High-Dimensional Propensity Score Matched Cohort Study.
    Sun SH; Chang CH; Zhan ZW; Chang WH; Chen YA; Dong YH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2721-2733. PubMed ID: 34621122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.
    Wu J; Song Y; Li H; Chen J
    Eur J Clin Pharmacol; 2009 Dec; 65(12):1169-74. PubMed ID: 19756555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and fibrates for preventing melanoma.
    Dellavalle RP; Drake A; Graber M; Heilig LF; Hester EJ; Johnson KR; McNealy K; Schilling L
    Cochrane Database Syst Rev; 2005 Oct; 2005(4):CD003697. PubMed ID: 16235336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-head comparison of fibrates versus statins for elevation of circulating adiponectin concentrations: a systematic review and meta-analysis.
    Sahebkar A
    Metabolism; 2013 Dec; 62(12):1876-85. PubMed ID: 24095632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
    Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
    BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between antihyperlipidemic agents and the risk of chronic periodontitis in patients with hyperlipidemia: A population-based retrospective cohort study in Taiwan.
    Wang AY; Lin GL; Keller JJ; Wang LH
    J Periodontol; 2024 May; 95(5):483-493. PubMed ID: 37793052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.